Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niagen Plus is a branded, pharmaceutical-grade nicotinamide riboside chloride (Niagen) product developed for intravenous and injectable administration to acutely raise nicotinamide adenine dinucleotide (NAD+) levels for wellness and longevity applications. It uses patented Niagen, a clinically studied form of nicotinamide riboside (a vitamin B3 derivative and NAD+ precursor), to increase circulating and cellular NAD+ more efficiently and with shorter infusion times than traditional NAD+ IV therapies, with pilot data showing up to ~20% NAD+ increase within 3 hours and improved tolerability. The product is supplied to clinics (including at-home injectable kits from partner pharmacies) for prescription-based IV drips, shots, or pushes, targeting cellular energy metabolism, mitochondrial function, and stress- or age-related NAD+ decline rather than a specific approved disease indication.[1][4][7][8][15][19]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Niagen Plus.